55, 65, and 75, over a maximum bene t period of six years. The combination plans incorporated both acceleration of bene ts and extension of bene t (EOB) riders. Both assumed a 5 ompound in ation option. A handful of sensitivities med to quantify the value of the natural hedge.

Statutory returns and after-tax pro ts for each type of plan were and quanti ed for two scenarios: a two-year AB pro-LONG TERM CARE pproximately 4 percent of the face value per month with INSURANCE SECTION pur-year EOB, and a three-year AB with a three-year EOB.

> that of the EOB. Comparing the two options advanced the notion that the natural hedge may favor the acceleration bene t, as the natural hedge in the 3-year/3-year scenario, where the acceleration bene t comprised a larger component of the total LTC bene t, turned out to be the stronger one.

The study did not measure the value of the AB separately from

CIETY OF

LONG- ERM CARE NE

MAPRIL 2020

AB claimants tend to enter claim status at a later point of disability than the average traditional LTCI claimant, trying to preserve the death bene t. While still applying lower incidence rates for policyholders with an EOB, we assumed the incidence rates were not as low as those with an AB alone. These policyholders may not be as inclined to preserve the death bene t, as doing so would mean forgoing the FOB.

- Recoveries: All claim terminations were assumed to be due to death, as combination policy claimants are generally less likely to recover their health due to their delay in entering initial claims.
- 9. Active life mortality: Various multiples of the 2000 Annuity Table were used, depending on the policyholders sex and the policy duration, in line with mortality assumptions generally used for traditional standalone LTC.
- 10. Disabled life mortality: This assumption was set signi cantly higher than the active-life mortality assumption and was in line with assumptions generally used for traditional standalone LTCI.
- 11. Lapse rate: Buyers were purchasing a combination life product to plan for potential LTC needs, so no one was assumed to have borrowed from the policy or to have used its non-forfeiture bene ts.
- 12. Claims administration expense: 4 percent of paid claims, in ating 3 percent per year from inception.
- 13. Death bene ts: These equaled the policy face amount minus any claims paid.
- 14. Interest rates: Present value calculations assumed the same interest rate expectations for all stochastic runs.

We stochastically measured the required PBEC for the death benet alone, for the AB with the death bene t, and for the EOB alone.

We found that the PBEC amount needed for both the morbidity and mortality components of the AB was smaller than what would have been needed for the mortality component alone. This is not to say the AB had no value, as the median scenario with AB and mortality had higher present value of future cash ow amounts than did that scenario with mortality alone. Yet the difference between the present value of cash ows for the extreme scenario we selected for the PBEC calculation and the median scenarios was smaller for the policy with the AB than for the standalone life policy without LTC bene ts.

In contrast, the morbidity risk component of the EOB alone showed a very large difference between the value of the selected extreme scenario and that of the median scenario. This



difference was due to two facts: no other bene ts are reduced when the EOB payments are being made, and there is no ability to increase premium rates. Essentially, this riders risk behaves like that of a traditional standalone LTC policy, but with a very lengthy elimination period and guaranteed premium rates. Extended bene ts have no natural hedge with other bene ts.

Our analysis suggests that at a minimum, quantifying capital requirements for combination life/LTC products would help manage the risk associated with having EOB riders. Further analysis is needed, including measurement of a range of additional risks and diversi cation across risks. An analysis of asset and interest rate risks could also be quite bene cial, but how important those two risks might be would depend on policy structure as well as any reinsurance protection.



Bruce Stahl, ASA, MAAA, is senior vice president and head of U.S. Individual Health at RGA Reinsurance Company. He can be reached at bstahl@rgare.com.



Elizabeth Dinc, ASA, is associate actuary, U.S. Individual Health at RGA Reinsurance Company. She can be reached at edinc@rgare.com.



Brian Kelly, FSA, is actuary, U.S. Individual Health at RGA Reinsurance Company. He can be reached at bkelly@rgare.com.